Clinical trials: Poor Performance Status
SCLC, Extensive Stage
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide
Small cell lung cancer (SCLC) is a rapidly proliferating, neuroendocrine tumor that accounts for about 15% of all lung cancers. Most patients have metastases at primary diagnosis involving sites like bone, adrenal glands, liver…
- Trial name
- SPACE (NCT04221529)
- Testing
- Atezolizumab
- Where
- 19 sites in Austria, Germany
- Volunteers
- 70 people
- Sponsor
- AIO-Studien-gGmbH
Melanoma
Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation
The purpose of this study is to find out what effects, good and/or bad, vemurafenib has on the patient and the melanoma. Specifically, the investigators want to know how well vemurafenib shrinks melanoma.
- Trial name
- NCT01474551
- Testing
- vemurafenib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
A Structured Walking Program or Standard Therapy in Cancer Patients Undergoing a Donor Bone Marrow Transplant
RATIONALE: A walking program may improve the ability to carry out daily activities after donor bone marrow transplant. PURPOSE: This randomized clinical trial is studying a structured walking program to see how well it works…
- Trial name
- NCT00445731
- Testing
- exercise intervention, management of therapy complications, observation
- Volunteers
- 115 people
- Sponsor
- University of Minnesota
Anorexia, Cachexia
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Infliximab may improve cancer-related weight loss, lack of appetite, and fatigue.
- Conditions
- Anorexia, Cachexia, Fatigue, Lung Cancer
- Trial name
- NCT00040885
- Testing
- infliximab, docetaxel
- Where
- 188 sites in United States
- Volunteers
- 67 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Poor Performance Status, Muscle Weakness
Innovative Training Program for Elderly in Need of Care Individuals
The goal of this randomized controlled study was to examine the effects of a 8 weeks innovative training regime (stochastic resonance whole-body vibration [SR-WBV] and virtual virtual games [VG]) in the skilling up phase on…
- Trial name
- NCT02102919
- Testing
- SR-WBV, Virtual Games (VG), Aktiv Tramp (Swiss Frei AG, Switzerland)
- Where
- Switzerland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bern University of Applied Sciences
Malignant Tumor of Lung, Poor Performance Status
Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status
Most of the lung cancer patients treated in hospitals in China are in advanced stage, accounting for more than 2/3 of all lung cancer patients, and some of the patients have a poor performence status.At present, most of the…
- Trial name
- NCT05826483
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Lung Cancer
Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients
In this randomized trial, we attempt to further define optimal palliative chemotherapy for elderly patients with advanced non-small cell lung cancer by comparing single agent treatment with weekly docetaxel versus combination…
- Trial name
- NCT00193323
- Testing
- Docetaxel, Gemcitabine
- Where
- United States
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- SCRI Development Innovations, LLC
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
This pilot clinical trial studies 6,8-bis(benzylthio)octanoic acid in treating patients with locally advanced or metastatic pancreatic cancer.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT01839981
- Testing
- 6,8-bis(benzylthio)octanoic acid
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Cognitive Impairment, Poor Nutrition
The PROtein Enriched MEDiterranean Diet and EXercise Trial for Older Adults At Risk of Undernutrition
PROMED-EX is a single-blind, parallel group randomised controlled trial to determine the effect of a PROtein enriched MEDiterranean diet (PROMED) in comparison to a PROtein enriched MEDiterranean diet and EXercise (PROMED-EX)…
- Conditions
- Cognitive Impairment, Poor Nutrition, Cognitive Decline
- Trial name
- PROMED-EX (NCT05166564)
- Testing
- A Protein Enriched Mediterranean Diet (PROMED) Intervention, A Protein Enriched Mediterranean Diet & Exercise (PROMED-EX) Intervention
- Where
- United Kingdom
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Queen's University, Belfast
Carcinoma, Non-Small-Cell Lung, ErbB Receptors
Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)
There is a medical need for improving treatment of poor performance status patients with EGFR driver mutations and documenting safety and tolerability of existing agents.
- Trial name
- NCT02695290
- Testing
- Afatinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients
The purpose of this study is to examine the efficacy and safety of using afatinib (BIBW 2992) to treat non-small cell lung cancer patients considered unfit for chemotherapy and have either suspected or confirmed Epidermal Growth…
- Trial name
- TIMELY (NCT01415011)
- Testing
- Afatinib (BIBW 2992)
- Where
- 15 sites in United Kingdom
- Volunteers
- 39 people
- Sponsor
- University College, London
Non-Hodgkins Lymphoma
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
The purposes of this trial are to decrease toxicity and improve treatment effectiveness elderly patients. With a short course of chemotherapy with cyclophosphamide, mitoxantrone, vincristine, and prednisone with concurrent…
- Trial name
- NCT00193479
- Testing
- Cyclophosphamide, Mitoxantrone, Vincristine
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- SCRI Development Innovations, LLC
Small Cell Lung Cancer
Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study
This is a multicenter, single-arm, exploratory clinical study designed to observe and evaluate the efficacy and safety of adebrelimab combined with oral etoposide for elderly patients and patients with poor performance status in…
- Trial name
- NCT07398560
- Testing
- Adebrelimab, Oral etoposide soft capsules
- Where
- China
- Volunteers
- 47 people
- Sponsor
- The Third Affiliated Hospital of Harbin Medical University
Poor Performance Status
Minocycline Treatment in Acute Hemorrhagic Stroke
The investigators will perform a double blind controlled study to investigate the efficacy of oral administration of 200 mg minocycline, on the neurological and functional outcome after acute hemorrhagic stroke and the effect on…
- Trial name
- Minocycline (NCT01388127)
- Where
- Israel
- Volunteers
- 150 people
- Sponsor
- Wolfson Medical Center
NSCLC Stage IV, KRAS P.G12C
Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status
ADEPPT is an international, multicentre, single-arm phase II trial. The protocol treatment consists of adagrasib, which is administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.The…
- Trial name
- ADEPPT (NCT05673187)
- Testing
- Adagrasib
- Where
- 18 sites in Belgium, France and 4 more
- Volunteers
- 68 people
- Sponsor
- ETOP IBCSG Partners Foundation
Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer
This phase II trial studies how well platinum-based chemotherapy works when given together with durvalumab in treating patients with stage IIIB or stage IV non-small cell lung cancer.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT04262869
- Testing
- Carboplatin, Durvalumab, Paclitaxel
- Sponsor
- Emory University
Poor Performance Status, Cognition - Other
Innovative Training Program for Elderly in Need of Care
The goal of this randomized controlled study was to examine the effects of a 8 weeks innovative training regime (stochastic resonance whole-body vibration [SR-WBV] and virtual virtual games [VG]) in the skilling up phase on…
- Trial name
- NCT02332083
- Testing
- SR-WBV, Exergame, Aktiv Tramp
- Where
- Switzerland
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Bern University of Applied Sciences
Lung Cancer
Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00986297
- Testing
- hypofractionated radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Poor Performance Status
Nighttime Feeding and Morning Endurance Performance
The purpose of this study is to investigate the influence of a nighttime feeding on next morning running performance, hydration status, and exercise metabolism in female endurance athletes.
- Trial name
- NCT02160873
- Testing
- chocolate milk
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Florida State University
Lung Cancer
Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00124618
- Testing
- cetuximab, radiation therapy
- Where
- 175 sites in United States
- Volunteers
- 58 people
- Sponsor
- Alliance for Clinical Trials in Oncology